Sydney, Australia, 31 January 2024: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to provide a summary of its activities for the quarter ended 31 December 2023.
Highlights for the quarter included:
-- FDA clears IND application for CHM 2101, phase 1A clinical trial set to begin in 2024
-- Phase 1A trial of CHM 1101 shows 55% Disease Control Rate in recurrent Glioblastoma (GBM); median survival of about 10 months post-treatment, exceeding historical averages
-- First patient dosed in Phase 1B trial of CHM 1101 for recurrent GBM
-- Phase 1B ADVENT-AML trial for CHM 0201 NK cells: - GMP manufacturing completed - Selection for presentation at ASH meeting
-- CHM 1301 demonstrates up to 300% increased cell killing capability in human ovarian and pancreatic cancer models
-- Entitlement offer raises ~A$4.5m to fund the Company’s continued clinical development
For more information, download the attached PDF.
Download this document
